Clinical Trial

Metformin Treatment of Patients with Hand Osteoarthritis

Study acronym: METRO
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated February 27, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
To compare metformin (2 g daily), or maximum tolerated dose, for 16 weeks with placebo as a treatment of hand osteoarthritis symptoms.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-04-11; most recent amendment 2025-02-25.
Status change: Not Yet Recruiting → Recruiting 2024-05-06
Trial Details
NCT Number NCT06367283
Lead Sponsor Marius Henriksen
Conditions Hand Osteoarthritis
Enrollment 150 participants
Start Date 2024-06-03
Primary Completion 2025-12 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2025-02-27